ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ADRX / earnings
AGIO (35) ZBIO (38) GENB (52) TRAX (44) ⌘ Pro Terminal →

ADARx Pharmaceuticals Inc. (ADRX) Next Earnings Date & Expected ±12.5% Move

$15.76 -7.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.52

ADARx Pharmaceuticals Inc. (ADRX) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D • SELL / AVOID Cap $1.82B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $15.76 (-7.29% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #287 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ADRX compare to AGIO and ZBIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGIO (Agios Pharmaceuticals Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -33.8%, cap $1.82B) and ZBIO (Zenas BioPharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADRX?
▼

For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #287 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.52 (-1.50%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510048
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-
Cash (12)Whales (3)SEC (13)Macro (11)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-4.5% Base Target
$24 Bull$15 Base$12 Bear
📬 FREE ADRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (48/100 Composite)
🔍 WHY ADRX SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (25% of score)

SEC XBRL Trailing 12 Months: 1.3% FCF Margin ($50.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
56
Grade C$17.97-1.9% Next Q
Q2 (-2Q)
53
Grade C-$17.63+1% Next Q
Q3 (-1Q)
51
Grade C-$17.81-11.5% Next Q
Current
48
Grade D$15.76-5.6% Hist 90D α
Trajectory: C (56) → D (48)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ADRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ADRX currently carries a cautious 48/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.12) and Max Pain ($16.55) forces dealer call-delta covering toward $24.37.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ADRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 48%NO 52%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.97 Expected Swing
$13.79 (-12.5%)Spot $15.76$17.73 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ADRX Quantitative Pre-Earnings Setup: 48/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (48/100)Model Risk Weight (52/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADRX)

  • ✓Walkthrough of ADRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ADRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.55%▼ SUPPORT BREAKDOWN
2026-11-02O $16.95H $17.03L $15.71C $15.76VOL 378.6K
RES: $19.21SUP: $16.58SMA50: $18.12
$23.74$21.56$19.38$17.21$15.04RES $19.21SUP $16.58$15.762026-09-252026-10-052026-10-142026-10-222026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADRX Butterfly Map → + Track ADRX →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADRX)

Health Care Rank #287 of 1016 ⚔️ AGIO vs ADRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADRX vs. AGIO, ZBIO, GENB, TRAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ADARx Pharmaceuticals Inc. (ADRX) ranks #287 by composite RQD confidence (48/100, grade D) and #273 by equity capitalization ($1.82B). Within this direct 5-issuer industry benchmark cohort, ADRX leads on earnings valuation at N/A trailing P/E, while AGIO leads on capital efficiency and profitability with -33.8% ROIC and 88.3% gross margin. GENB currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with ADRX at 48/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ADRX ACTIVE
ADARx Pharmaceuticals Inc.
D 48/100 — — — -7.29% $1.82B Benchmark Subject
AGIO
Agios Pharmaceuticals Inc.
D- 35/100 — 88.3% -33.8% -1.96% $1.82B /agio-vs-adrx →
ZBIO
Zenas BioPharma Inc.
D- 38/100 — — -35.0% -2.71% $1.85B /zbio-vs-adrx →
GENB
Generate Biomedicines Inc.
D+ 52/100 — — — -8.64% $1.86B /genb-vs-adrx →
TRAX
First Tracks Biotherapeutics Inc.
D 44/100 — — -35.0% -0.07% $1.89B /trax-vs-adrx →

2. ADRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

ADARx Pharmaceuticals Inc. (ADRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.82B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ADRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, ADARx Pharmaceuticals Inc. (NASDAQ: ADRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $15.76 (-7.29% 1D, market cap $1.82B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ADRX ranks #287 in composite RQD confidence.

How does ADRX compare to AGIO and ZBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ADRX carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AGIO (Agios Pharmaceuticals Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -33.8%, cap $1.82B) and ZBIO (Zenas BioPharma Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, ADRX leads on earnings multiple (N/A) while AGIO leads on capital efficiency (-33.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADRX?

For ADARx Pharmaceuticals Inc. (ADRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #287 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADRX trading relative to its 50-day, 200-day, and 52-week technical levels?

ADRX last traded at $15.76 (-7.29% on volume of 378,699 shares), positioning the stock -13.02% below its 50-day simple moving average ($18.12) and -13.17% below its 200-day simple moving average ($18.15). Across its 52-week range of $15.71 to $23.21, ADRX sits at the 0.7% percentile with a 14-day RSI of 29.7 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($13.79 to $17.73).

Direct Sub-Reports: ADRX RQD Cockpit ADRX 12M Forecast ADRX Earnings & Move ADRX Dividends & DRIP ADRX Insiders & 13F ADRX Whale Options ADRX Profit Sankey ADRX News & Why
ROARABLE RATING BRIEF • RQD 48/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ADRX — ADARx Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:12:53Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

ADRX carries an RQD Score of 51 and a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. The rating cites ROIC of 0% and FCF yield of 0%. For a prospective investor, the cash-generation case is currently unproven in the source data.
  • Whale 13F Flow: 5 / 20. Described as institutional accumulation and options positioning. This is the lowest pillar and suggests weak institutional support in the source data.
  • Insider Conviction: 9 / 20. Described as SEC Form 4 and Congressional PTR cluster flow. Insider signals are modest per this pillar.
  • Macro Regime Fit: 12 / 20. Beta of 1.0 and sector sensitivity are cited. The stock is rated as moving in line with the broader market rather than offering defensive or differentiated behavior.
  • Forensic Balance Sheet: 13 / 20. Altman Z of 2.5, Piotroski F of 6/9, and Debt/Equity of 0.5 are cited. This is the strongest pillar, indicating a balance sheet that is more stable than the cash-flow and flow pillars.

Investor implications: the upside case rests on the balance-sheet strength and on the catalyst flow below; the valuation tradeoff is that without reported earnings, cash flow, or P/E data, the rating cannot distinguish between a pre-profit growth profile and a stalled one. The rating's sell label reflects weak cash returns and institutional flow rather than balance-sheet distress.

2. Business Model, Unit Margins & SEC Financial Trajectory

ADARx Pharmaceuticals Inc. (ADRX) operates in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity capitalization of $1.82B, gross margin of —, operating margin of —, and return on invested capital (ROIC) of —.

## Recent Catalysts & News Wire Analysis

Per the Recent News and Catalysts feed for ADRX:

  • Analyst activity (Market Wire, YELLOW): A headline references UBS initiating coverage with a buy rating on the siRNA platform. Another references Zacks Research upgrading the stock to Hold (CATALYST, GREEN). These are the most directly rating-relevant items in the feed.
  • Pipeline narrative (CATALYST, GREEN): An RTTNews piece asks whether the siRNA pipeline can unlock multiple growth opportunities. The headline frames the pipeline as the growth driver; the source does not provide pipeline detail.
  • Price and forecast items (Market Wire, YELLOW): A TradingView forecast/price-target piece and a TradingKey price print (18.130, +0.320%) are listed. Note that the TradingKey print differs from the market-data price of 17 and -4.76%; the source does not reconcile the two.
  • Broader healthcare commentary (Market Wire, YELLOW): A Globe and Mail piece covers ADRX alongside AbbVie and Incyte.

Risk watch items: the feed's own price prints conflict, and the catalyst headlines are analyst-sentiment and narrative items rather than reported results.

Proprietary signals: — (The Butterfly graph lists no proprietary signals.)

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case: Balance-sheet strength (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) plus recent UBS buy initiation and Zacks upgrade to Hold on the siRNA platform support the upside case. With Fundamental Cash Engine at 12/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $15.71 – $23.21 52-week range.
  • 🐻 Primary Bear Case: Zero ROIC and FCF yield, a 5/20 whale 13F flow score, and a Roarable Sell rating leave the stock without cash returns or institutional support in the source data. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations.

  • Key Question #1: Why does the rating show ROIC and FCF yield of 0%, and what is the company's path to positive cash generation?
  • Key Question #2: Which price is current: the market-data price of 17, or the 18.130 print in the TradingKey headline?
  • Key Question #3: What do the UBS buy initiation and Zacks Hold upgrade rest on, and what are their price targets?

ADRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for ADARx Pharmaceuticals Inc. (ADRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ADRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADRX Bull vs. Bear Conversation Board — What's Your Call at $15.76?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ADRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull Growth & Tech Investor 🐂 BULLISH 🎯 Target: $18.75 (+19.0%)
📌 Pinned Debate

Balance-sheet strength (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) plus recent UBS buy initiation and Zacks upgrade to Hold on the

Don't sleep on ADRX's setup in Health Care. Balance-sheet strength (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) plus recent UBS buy initiation and Zacks upgrade to Hold on the siRNA platform support the upside case.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (48/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $12.29 (-22.0%)
Spot @ $15.76

Valuation & margin reality check on ADRX at $15.76 before chasing here

I respect the product at ADARx Pharmaceuticals Inc., but the stock at $15.76 is a different story. Valuation & margin reality check on ADRX at $15.76 before chasing here. FCF yield is 0.0% and RQD sits at 48/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%